Riskpilot← Back to searchSign inGet full accessCrelab Instruments Aktiebolag
ABActiveOrg 5563067072Kalvhagen 20Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19871-4 employees
Revenue 2024
SEK 1,9M
-2% vs 2023
EBITDA margin
4.7%
-78% vs 2023
Equity ratio
79.4%
Financial strength
Net profit 2024
SEK 85K
-74% vs 2023
| Revenue | SEK 1,9M | -2% |
| EBITDA | SEK 89K | -78% |
| Net profit | SEK 85K | -74% |
| Total assets | SEK 2M | -10% |
| Equity | SEK 1,6M | -7% |
| Employees | — | — |
Legal name
Crelab Instruments Aktiebolag
Org number
5563067072
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2 oktober 1987
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska bedriva försäljning och service av laboratorieutrustning samt därmed förenlig verksamhet inom läkemedelsindustrin, universitets och forskningsinstitut och petrokemisk industri.
Address
Kalvhagen 20
Phone
+46317489626
Email
helen.andersson@crelab.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 583 | 1 322 | 2 969 | 1 936 | 1 888 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 503 | 55 | 631 | 404 | 89 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 503 | 55 | 631 | 404 | 89 |
| Net financials | −6 | — | 1 | 6 | 20 |
| Profit before tax | 497 | 55 | 632 | 409 | 109 |
| Tax | −5 | −14 | −132 | −88 | −24 |
| Net profit | 492 | 41 | 500 | 321 | 85 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 273 | 1 478 | 1 967 | 2 192 | 1 980 |
| Equity | 1 597 | 1 256 | 1 567 | 1 693 | 1 573 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 676 | 222 | 400 | 498 | 407 |
| Total debt | 676 | 222 | 400 | 498 | 407 |
EBITDA margin
4.7%
This company
15.8%
Market median
-70% vs market
20202024
Equity ratio
79.4%
This company
38.2%
Market median
+108% vs market
20202024
Return on equity
5.4%
This company
18.4%
Market median
-71% vs market
20202024
Net profit margin
4.5%
This company
8.1%
Market median
-44% vs market
20202024
Asset turnover
0.95×
This company
1.12×
Market median
+15% vs market
20202024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GV Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (2) | ||
KE Chief Auditor | Chief Auditor | 2020 – 2022 |
ER Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Chairman | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Crelab Instruments Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Katharina Elisabet Johanna Norberg | Chief Auditor | 0 companies |
| Erik Robin Vesterberg | Chief Auditor | 0 companies |
| German Vikholtz | Chief Executive Officer | 0 companies |
| Jonathan Ekman Andersson | Deputy Board Member | 0 companies |
| Inger Helen Cuellar Andersson | Chairman | 0 companies |